A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD
A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study of Orally Administered EDP-305 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (SAD), Multiple Ascending Doses (MAD) and the Effect of Food on EDP-305 Pharmacokinetics in Healthy Subjects, and of Multiple Ascending Doses (MAD) in Subjects With Presumptive NAFLD
Sponsor: Enanta Pharmaceuticals, Inc
A PHASE1 clinical study on Presumptive NAFLD, this trial is completed. The trial is conducted by Enanta Pharmaceuticals, Inc and has accumulated 9 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Nov 2022 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 4 earlier versions
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Jun 2017 — Sep 2017 [monthly]
Recruiting PHASE1
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Sep 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Enanta Pharmaceuticals, Inc
- Pharmaceutical Research Associates
For direct contact, visit the study record on ClinicalTrials.gov .